Showing results (181-190 of 286) with videos related to

Sort By:
Pageof 29
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.
Dermatologic Clinics|September 10, 2017
Integrating Skin Cancer-Related Technologies into Clinical PracticeRichard R Winkelmann, Aaron S Farberg, Alex M Glazer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Pageof 29